With sales exceeding US$146 billion over the past decade, U.S. pharmaceutical giant Merck’s Keytruda has become the ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory ...

Alteogen, a bio platform company, announced through a disclosure on November 14 that it achieved consolidated cumulative sales of 151.4 billion won ...

Abstract: Digital channelization plays an important role in passive sensing. In this paper, a novel efficient multi-antenna digital channelization structure for FPGA implementation is proposed. From ...

President Donald Trump put pharmaceutical CEOs on notice, demanding they lower drug prices or he promised to get involved. He penned a letter to 17 CEOs in July, outlining what he wants from the ...

Abstract: Microservice architecture offers great scalability and flexibility to the development of online servicessystems. Performance anomalies, which happen frequently due to code bugs or runtime ...

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

Oct 30 (Reuters) - Merck & Co (MRK.N), opens new tab posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus ...

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise. The pharmaceutical company reported net income of $5.79 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...